Glucose increases interleukin-12 gene expression and production in stimulated peripheral blood mononuclear cells of type 2 diabetes patients

• Published in: Biomedical Journal Vol. 37; no. 5; pp. 293 - 297
• Main Authors: Wu, Huang-Pin, Chu, Chien-Ming, Kuo, Sheng-Fong, Hua, Chung-Ching, Wu, Shao-Yun, Chuang, Duen-Yau
• Format: Journal Article
• Language: English
• Published: United States Medknow Publications and Media Pvt. Ltd 01.09.2014; Elsevier Limited; Elsevier
• Subjects: Adult; Aged; Atherosclerosis; Blood cells; Cytokines; Deoxyribonucleic acid; Dextrose; Diabetes; Diabetes Mellitus, Type 2 - metabolism; DNA; Female; Gene expression; Gene Expression Regulation - drug effects; Genetic aspects; Glucose; Glucose - metabolism; Humans; Hyperglycemia; Insulin; Interleukin-12; Interleukin-12 - genetics; Interleukin-12 - metabolism; Leukocytes, Mononuclear - metabolism; Lipopolysaccharides - pharmacology; Male; Middle Aged; osmolarity; peripheral blood mononuclear cells; Physiological aspects; Proteins; Sepsis; Statistical analysis; Studies; Tumor necrosis factor-TNF; Type 2 diabetes
• DOI: 10.4103/2319-4170.132887
• ISSN: 2319-4170; 2320-2890

Lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs) of type 2 diabetes patients produce more interleukin (IL)-12 under glucose treatment. The aim of this study was to determine whether increased IL-12 response in hyperglycemic LPS-stimulated PBMCs is due to increased gene expression or osmolarity. LPS-stimulated PBMCs of 13 type 2 diabetes patients and 8 healthy controls were used for culture in the presence or absence of glucose or mannitol for 24 h. The IL-12 gene expressions of PBMCs and IL-12 protein levels in supernatants were evaluated. After 24 h, the stimulated PBMCs of diabetes patients expressed more IL-12 mRNA and produced more IL-12 protein following glucose treatment than those without glucose treatment and with mannitol treatment. Stimulated PBMCs of controls did not express more IL-12 mRNA and produce more IL-12 protein following glucose treatment than those without glucose treatment and with mannitol treatment. Glucose increases the IL-12 production in stimulated PBMCs of diabetes patients through increased IL-12 gene expression.